Free Trial

Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix logo
$7.22 -0.08 (-1.10%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$7.22 0.00 (0.00%)
As of 05/22/2025 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCUL vs. PCVX, KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, and AKRO

Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Vaxcyte (PCVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Ocular Therapeutix vs.

Vaxcyte (NASDAQ:PCVX) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.

Vaxcyte presently has a consensus target price of $136.50, suggesting a potential upside of 302.06%. Ocular Therapeutix has a consensus target price of $16.25, suggesting a potential upside of 125.07%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vaxcyte is more favorable than Ocular Therapeutix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10
Ocular Therapeutix
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Ocular Therapeutix received 388 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 70.32% of users gave Ocular Therapeutix an outperform vote.

CompanyUnderperformOutperform
VaxcyteOutperform Votes
55
78.57%
Underperform Votes
15
21.43%
Ocular TherapeutixOutperform Votes
443
70.32%
Underperform Votes
187
29.68%

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ocular Therapeutix has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$402.27M-$3.99-8.51
Ocular Therapeutix$59.65M19.28-$80.74M-$1.15-6.28

Vaxcyte has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

In the previous week, Vaxcyte had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 15 mentions for Vaxcyte and 10 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.56 beat Vaxcyte's score of 1.41 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
15 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocular Therapeutix
9 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Vaxcyte has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Vaxcyte's return on equity of -23.53% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -23.53% -22.20%
Ocular Therapeutix -283.74%-45.18%-30.87%

Summary

Vaxcyte beats Ocular Therapeutix on 11 of the 18 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16B$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-5.479.0626.7119.71
Price / Sales19.28251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book9.146.456.774.50
Net Income-$80.74M$143.98M$3.23B$248.22M
7 Day PerformanceN/A0.38%0.48%-0.78%
1 Month Performance-8.06%2.14%9.10%11.53%
1 Year Performance24.48%-0.33%18.56%8.99%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
4.2195 of 5 stars
$7.22
-1.1%
$16.25
+125.1%
+20.3%$1.16B$59.65M-5.47230Gap Up
PCVX
Vaxcyte
3.0825 of 5 stars
$31.59
+1.4%
$136.50
+332.1%
-52.4%$4.08BN/A-6.87160Positive News
KRYS
Krystal Biotech
4.9053 of 5 stars
$139.43
+5.5%
$218.63
+56.8%
-26.0%$4.03B$333.45M46.63210Positive News
CYTK
Cytokinetics
4.1473 of 5 stars
$32.13
+1.4%
$74.44
+131.7%
-48.5%$3.84B$19.22M-5.97250
RYTM
Rhythm Pharmaceuticals
3.9413 of 5 stars
$58.97
+2.8%
$75.38
+27.8%
+63.9%$3.75B$130.13M-13.62140Positive News
PTCT
PTC Therapeutics
4.1846 of 5 stars
$46.01
+4.0%
$61.92
+34.6%
+17.8%$3.65B$1.77B-7.751,410
SRPT
Sarepta Therapeutics
4.8147 of 5 stars
$36.37
+0.3%
$131.22
+260.8%
-69.8%$3.57B$2.23B29.10840Analyst Forecast
High Trading Volume
RNA
Avidity Biosciences
1.906 of 5 stars
$29.33
+5.2%
$66.38
+126.3%
+4.0%$3.53B$10.90M-10.18190Options Volume
SWTX
SpringWorks Therapeutics
2.3586 of 5 stars
$46.12
-0.3%
$52.57
+14.0%
+4.5%$3.46B$191.59M-13.25230Positive News
High Trading Volume
RARE
Ultragenyx Pharmaceutical
3.9602 of 5 stars
$36.09
+2.8%
$90.93
+152.0%
-13.6%$3.32B$590.69M-5.691,310Positive News
AKRO
Akero Therapeutics
3.8084 of 5 stars
$41.53
+4.2%
$76.29
+83.7%
+138.9%$3.31BN/A-11.0730Insider Trade
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners